Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.
| Revenue (TTM) | $329.43B |
| Gross Profit (TTM) | $270.09B |
| EBITDA | $173.68B |
| Operating Margin | 42.50% |
| Return on Equity | 59.80% |
| Return on Assets | 18.70% |
| Revenue/Share (TTM) | $74.19 |
| Book Value | $7.72 |
| Price-to-Book | 4.97 |
| Price-to-Sales (TTM) | 0.52 |
| EV/Revenue | 3.671 |
| EV/EBITDA | 8.18 |
| Quarterly Earnings Growth (YoY) | -20.60% |
| Quarterly Revenue Growth (YoY) | 2.10% |
| Shares Outstanding | $3.34B |
| Float | $3.17B |
| % Insiders | 0.00% |
| % Institutions | 9.90% |
Volatility is currently expanding
Novo Nordisk on Tuesday struck its second licensing deal since receiving a poor reception from investors after presenting its long-term strategy.
Jiangsu Hengrui Pharmaceuticals , China's largest drugmaker by market value, said on Tuesday it will license global rights to its weight-management drug HRS-1596 to Novo Nordisk A/S in a deal worth up to $2.6 billion.
Bristol Myers Squibb's Growth Portfolio sales rose 15% in the second quarter, and management raised its 2026 revenue guidance to $49 billion to $50 billion. Novo Nordisk expects 2026 adjusted sales to range from flat to down 6% at constant exchange rates, even after raising that outlook in August.
Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
The latest rebalance of VettaFi's Thematic Rotation Quality Momentum Screened Index (TQRMS), tracked by the NBI Thematic Rotation ETF (NTHM:TSX), reshapes the portfolio around a new set of themes. GLP-1 weight loss drug manufacturers and midstream energy join the index, while battery technology & storage and software-as-a-service (SaaS) exit.
The Swedish drug-delivery company agreed to license its PharmaShell technology to Novo Nordisk for up to five development programs targeting obesity, type 2 diabetes and other cardiometabolic conditions. Novo Nordisk will use the technology to develop injectable drugs that could be administered monthly or quarterly, with Nanexa eligible for upfront and milestone payments as well as royalties on future sales.
Novo Nordisk agreed to license and develop the technology, which could cut the frequency patients need to inject its obesity and diabetes drugs.
Shares in Swedish drug-delivery company Nanexa more than doubled their value in early Friday trading after it signed a global licensing deal with Novo Nordisk worth up to about €1.17 billion ($1.33 billion).
At its September 21 Capital Markets Day, Novo Nordisk A/S outlined plans to launch more than five multi-blockbusters by 2030 and deliver over DKK 150 billion in pipeline sales by 2035. CEO Maziar Doustdar said Novo will prioritize asset quality over deal size, with bolt-on acquisitions likely to be the focus while remaining open to larger deals. Meanwhile, in Q2, sales of the Wegovy pill were up 42.6% quarter-on-quarter to about DKK 3.2 billion.
Novo set out ambitions to launch more than five potential multi-blockbuster drugs by 2030 on Monday, but shares fell 8%. Analysts said the update offered little new to restore confidence after the company's shares tumbled over the past two years.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on NVO and any ticker you trade — then tracks every position and per-strategy win rate.
